Pediatric Conjugated Hyperbilirubinemia — Diagnosis and Treatment

See online here

Conjugated hyperbilirubinemia is a common affliction seen in infants and young children. With a multitude of etiologies, it becomes important to know how this condition may present and how it may be managed.

Introduction

Bilirubin is a pigment (tetapyrrole) that is formed in the normal catabolic pathway from the heme group. It is thus a waste product of mature red blood cell destruction. According to its metabolism, it can be classified as conjugated (correlated with direct bilirubin) and unconjugated bilirubin (correlated with indirect bilirubin).
Hyperbilirubinemia can be defined as an elevated concentration of bilirubin in the blood, which is expressed in the form of jaundice (also called icterus). Jaundice appears when the yellow bilirubin pigments are deposited in the skin, sclera, mucous membranes and other tissues leading to yellowish discoloration.

The normal range of bilirubin is:

- Serum total bilirubin between 0.2 and 1.2 mg/dL
- Serum direct bilirubin between 0.1 and 0.4 mg/dL

It is considered as hyperbilirubinemia when:

- Serum direct bilirubin is \( \geq 1 \) mg/dL (if total bilirubin is < 5mg/dL)
- Serum conjugated bilirubin is > 20 \% of total bilirubin (if total bilirubin is > 5mg/dL)

Differential Diagnosis of Pediatric Conjugated Hyperbilirubinemia

In some newborn babies, especially premature babies, a slight increase of bilirubin can be considered normal; however, it must always be studied, because a high level of bilirubin at the expense of conjugated bilirubin can never be considered normal.

In the study of hyperbilirubinemia, it is very important to distinguish the cause to treat the patient appropriately. There are many diseases that can cause hyperbilirubinemia,
but they can be broadly classified into two groups: extrahepatic disorders (pre-hepatic causes like hemolysis due to intrinsic defects of red blood cells or extrinsic causes leading to red blood cells rupture, or post-hepatic causes including obstruction of biliary passage) and intrahepatic disorders (liver diseases such as cirrhosis, hepatitis, medications, infections or blockage of the bile duct).

It is important to know that diseases that tend to reduce the secretion of conjugated bilirubin or reduce the flow of bile into the intestine, elevate the total or mixed bilirubin, or predominantly the conjugated bilirubin. Likewise, conjugated bilirubin elevated levels can indicate a hepatobiliary disease.

**History of Pediatric Conjugated Hyperbilirubinemia**

To make a diagnosis of hyperbilirubinemia in children, it is very important to take a good clinical history, including the parents and close relatives’ pathological antecedents, the possible existence of consanguinity between the parents, possible complications during pregnancy and delivery, possible exposure to an infectious disease before or after birth (such as hepatitis, malaria, cytomegalovirus and leptospirosis) among others.

Physical examination is very important in the diagnosis of hyperbilirubinemia. The main sign is jaundice or yellowish discoloration of the sclera, mucous membranes, and the skin. The urine of the baby becomes dark and depending on the cause, the feces can be white.

It is also extremely important to perform a neurological examination of the baby (reflexes and external stimuli response) in order to determine the central nervous system affliction (that is known as kernicterus or bilirubin encephalopathy). This indicates the presence of severe hyperbilirubinemia.

Other important parameters that must be examined include growth parameters, vital signs, cardiac and respiratory murmurs, abdominal examination (in order to determine the abnormal growth of the spleen or liver).

**Laboratory Tests of Pediatric Conjugated**
Hyperbilirubinemia

**The laboratory tests required are:**

1. Complete blood cell count which is necessary for screening of hemolysis
2. Serum aminotransferases levels are done to study the function of the liver. They include aspartate aminotransferase [AST] and alanine aminotransferase [ALT]
3. Serologic screening for viruses
4. Alkaline phosphatase [ALP] since a rise in it can indicate bile ducts obstruction
5. Gamma-glutamyl transpeptidase [GGT] whose levels may help to differentiate a hepatic source of the elevated ALP from other causes
6. Fractionated bilirubin

In other terms, **liver function tests (LFTs or LFs)** are necessary for diagnosis and they include prothrombin time (PT/INR), activated Partial Thromboplastin Time (aPTT), albumin, bilirubin (direct and indirect), and liver transaminases (AST and ALT). Biopsy and imaging studies are usually reserved for those cases with an unclear diagnosis or discard obstructive pathologies.

Genetic Defects of Pediatric Conjugated Hyperbilirubinemia

There are a lot of inherited syndromes related to hyperbilirubinemia and intrahepatic cholestasis. Many of them are related to genetic mutations including the gene **SERPINAI (alpha 1-antitrypsin)**, **JAG1 (causing Alagille syndrome)**, **ATP8B1 (also known as FIC1)**, **ABCB11 (bile salt export pump [BSEP])**, **MDR3 (ABCB4)**, and **MRP2 (causing Dubin-Johnson syndrome)**.

Alagille Syndrome

Alagille syndrome is an **autosomal dominant genetic disorder that can affect many parts of the body**. The mutation occurs in the short arm of chromosome 20 (20p12). One in every 20 or 30 mutations occurs de novo. One of the most affected organs in Alagille syndrome is the liver and the bile ducts. These bile duct malformations cause a bile build up in the liver i.e. cholestasis, which causes liver scarring thereby altering its functioning.

The signs and symptoms arising from liver damage in Alagille syndrome may include **jaundice, itchy skin, and xanthomas**. However, the heart is also affected and the patient may have pulmonic stenosis. In pulmonic stenosis, there is an impaired blood flow from the heart into the lungs. There may also be co-existent congenital heart diseases such as ventricular septal defects, tetralogy of Fallot etc. The brain, spinal cord, kidneys and blood vessels can also be affected.

Alagille syndrome has **characteristic facial features**. The patient usually has a triangular face, a broad and prominent forehead, wide nasal bridge, deep-set eyes and a small, pointed chin. The diagnosis is difficult and requires at least 3 of the typical physical features, the evidence of bile ductus obstruction (cholestasis) and a liver biopsy.

Treatment is dependent on the severity of the disease in Alagille syndrome. In case of mild disease, **ursodeoxycholic acid is administered to facilitate the biliary flow and antihistamines like diphenhydramine are given to control the pruritus**. For severe cases, a **liver transplant may be required**. Vitamin supplementation has been
found to be helpful especially with vitamins A, D, E and K. Zinc supplementation is also beneficial. These patients have an inability to absorb these vitamins and thus, supplementation helps in the facilitation of optimal patient growth.

Biliary Atresia

Biliary atresia is another very frequent cause of conjugated hyperbilirubinemia. The patient may have a complete or partial obstruction of the extrahepatic biliary tree at different points; however, the most common parts affected are the hepatic duct and the common bile duct. Partial obstruction is usually caused by a fibro-inflammation along the bile duct.

This fibro-inflammation is due to a perinatal disease, usually a viral infection that affects the biliary duct mucosa. When the infection progresses, the immunologic system responds and there is epithelial thickening in the mucosa leading to obstruction of the duct. As time progresses, the proliferating mucosa develops sclerosis and fibrosis, causing total duct atresia during the first month of life and its subsequent complications.

In the diagnosis of biliary atresia, it is also very important to take a complete clinical history, perform good physical examination and laboratory tests as mentioned earlier; however, in this case, imaging techniques (like ultrasound, hepatobiliary scan (HIDA) or even an intraoperative cholangiogram) can be very useful in the diagnosis of the disease.

No primary medical treatment is effective in the correction of biliary atresia; therefore, once the diagnosis is confirmed, a surgical intervention is necessary and in many cases, the surgery itself can be diagnostic. It can be done as an intraoperative cholangiogram or a Kasai portoenterostomy. Liver transplantations are reserved for severe cases.

Choledochal Cysts

Finally, choledochal cysts, better known as congenital bile duct dilatation, can also cause conjugated hyperbilirubinemia. The most common congenital abnormality of choledochal cysts is the enlargement of extrahepatic bile duct (1 from every 100000-150000 newborns). The symptoms of choledochal cysts can present at any age. However, they are characteristically seen with obstructive jaundice along with abdominal pain in infants and children. They have a female predilection with a female to male ratio of about 3–4:1. They are more common in certain Asian races.

Types of choledochal cysts: Initially, three types of choledochal cysts were described but Todani and associates further classified these into five types which are described below.

1. **Type I:** There is dilation of the common bile duct. It could be cystic, focal or fusiform (seen in 90–95% of cases)
2. **Type II:** A diverticulum of the extrahepatic bile duct is seen here.
3. **Type III:** characterized by choledochoceles
4. **Types IV:** It is of two types, Type IV-A and Type IV-B. Type IV-A is the second most common type and is defined as both intrahepatic and extrahepatic dilation of the biliary tree. Type IV-B involves the rare malformation of multiple extrahepatic cysts.
5. **Type V:** this type is also known as Caroli’s disease when it is associated with hepatic fibrosis. Type V includes single or multiple intrahepatic cysts.
5 types of Choledochal cysts. Type I: dilatation of extrahepatic biliary duct; Type II: Cyst from common bile duct (CBD); Type III: choledochocele or dilatation of distal part of CBD, type IV: dilatation of both extrahepatic and intrahepatic duct; Type V: Caroli disease, Dilatation of intrahepatic duct only. CHD: common hepatic duct, LHD: left hepatic duct and RHD: right hepatic duct.

It is commonly seen in infants aged 1 to 3 months. Clinically, they present with fever, pain in the right upper quadrant of the abdomen, acholic or pale stools and hepatomegaly and this picture is similar to biliary atresia. In case of prenatal diagnosis of choledochal cyst, jaundice is not apparent until 1 to 3 weeks after birth. When choledochal cyst presents later, it does not become clinically evident until after 2 years of age and may present with a classic triad of abdominal pain, palpable abdominal mass, and jaundice; of which two are found in almost 85% children at the time of presentation.
Other common features are cholangitis, pancreatitis and biliary peritonitis due to rupture of the cyst.

Laboratory investigations, as well as imaging, are necessary for a definitive diagnosis. Laboratory investigations include the **conventional liver functions tests, CBC and coagulation profiles**. Imaging studies include ultrasound scanning, computed tomography, magnetic resonance imaging, magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography among others.

**Ultrasound scanning** helps in the diagnosis of choledochal cysts and it has a very high specificity of 97% in children but a low diagnostic accuracy antenatally. Thus, it is used as a primary diagnostic imaging modality for neonatal jaundice that persists more than 2 weeks post birth. It is also useful in differentiation between choledochal cysts and biliary atresia.

The use of **computed tomographic scans** for diagnosing choledochal cysts is controversial. Small size cysts or choledochoceles are missed on CT scans but are easily seen on magnetic resonance cholangiopancreatography (MRCP). CT scanning may be better than MRCP in the postoperative period for detecting the location of the biliary-enteric anastomosis and in defining any stenosis thereof.

**Magnetic resonance cholangiopancreatography (MRCP)** is superior at detecting and defining lesions. Nowadays, it is considered as the gold standard in the imaging of choledochal cysts. However, it has a drawback of not being able to precisely detect any anomalous pancreaticobiliary union. Nevertheless, this does not play a major role in determining patient management. In addition, the sensitivity of MRCP is more in adults than in infants.

**Endoscopic retrograde cholangiopancreatography (ERCP)** is the best tool for knowing the biliary anatomy and is thus helpful in the diagnosis of choledochal cysts.

Treatment primarily includes **surgical intervention**. An internal drainage procedure known as a cyst-enterostomy (that could be either cyst-duodenectomy or cyst-jejunostomy) was done in the past for surgical treatment of choledochal cysts. However, various complications were seen postoperatively such as malignancy in the remaining cyst, pancreatitis, and cholangitis. Thus, they were abandoned.

At present, the recommended surgical procedure is **cyst excision and then Roux-en-Y hepaticojejunostomy or choledochojejunostomy**. Because of cyst excision, there is a reduction in the incidence of stricture formation postoperatively. Other alternatives i.e. hepatic duodenotomy have been suggested so that the anastomosis is accessible to ERCP in case of postoperative complications. However, the use of hepatic duodenotomy has not been widely accepted as it can cause biliary reflux and cholangitis.

Post cyst excision, **probing and copious lavage of the intrahepatic ducts with saline** is necessary to remove sludge and possible stones from the ductal system completely. Furthermore, the obstruction can be present in the proximal biliary system that can be dilated. Consequently, prior to excision of the cyst, an intraoperative cholangiography is obligatory.

**References**

Brough, A.J. and Bernstein, J., 1974. Conjugated hyperbilirubinemia in early infancy: A


**Legal Note:** Unless otherwise stated, all rights reserved by Lecturio GmbH. For further legal regulations see our [legal information page](#).